An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies

The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in NKTR-102 studies and to evaluate the safety of long-term exposure to NKTR-102.

In additional the study will track disease progression and survival status in subjects who have ongoing clinical benefit from continued treatment with NKTR-102.

• Malignant Solid Tumour
• Breast Cancer
• Ovarian Cancer
• Colorectal Cancer

Inclusion:

Subjects must fulfill Inclusion Criteria to be eligible for study entry:

1. Previous treatment with NKTR-102 with demonstrated clinical benefit
2. ECOG performance score of 0 or 1
3. Adequate bone marrow and organ function at screening
4. Receive the first dose of NKTR-102 int he extension study within 12 weeks of receiving their last dose of the NKTR-102 in the original protocol

Exclusion:

Subjects meeting any of the Exclusion Criteria are ineligible for enrollment:

1. Received intervening anti-cancer therapy between last dose int he original protocol and administration of the first dose in the extension study
2. Had major surgery within 4 weeks prior to Day 1 of Cycle 1 or minor surgery within 2 weeks prior to Day 1 Cycle 1.
3. Received cytochrome P450 #4A(CYP3A4)inducers or inhibitors
4. Receiving anti-cancer biologic agents with 28 days of Day 1 Cycle 1
5. Have unresolved or irreversible NKTR-102 related ongoing AE occurring during the original protocol
6. Have diarrhea.